| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $48.9M | +181.8% |
| SG&A Expense | $13.8M | +159.9% |
| Operating Income | -$62.7M | -175.3% |
| Income Tax | $0 | — |
| Net Income | -$57.6M | -179.7% |
| EPS (Basic) | -$2.93 | +43.1% |
| EPS (Diluted) | -$2.93 | +43.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $47.1M | -23.7% |
| Short-term Investments | $63.0M | +423.8% |
| Current Assets | $111.9M | +50.9% |
| Total Assets | $117.2M | +51.2% |
| Current Liabilities | $10.5M | +114.1% |
| Total Liabilities | $10.5M | +95.6% |
| Stockholders' Equity | $106.6M | +295.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$54.2M | -199.5% |
| Capital Expenditures | $95K | -12.8% |
| Investing Cash Flow | -$49.7M | -314.0% |
| Financing Cash Flow | $89.2M | +8.9% |
| Free Cash Flow | -$54.3M | -198.2% |